🔗 Share this article

Given that America continues making sweeping adjustments to its vaccine recommendations, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by casting doubt on coronavirus vaccines during the pandemic and has focused upon possible deaths after Covid immunization in her brief time at the FDA.

Scheduled Shifts to Childhood Vaccine Program

Health officials were set to reveal radical revisions to the childhood immunization program earlier this month, bringing the US with Denmark’s immunization schedule, it is understood – a significant shift that would place the US at odds with many the global community with insufficient data for improved outcomes. The announcement has been delayed until the coming year.

Instead of the top vaccines chief, Høeg is set to present at the meeting. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this year.

A Shift at the FDA

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it suggests a greater focus upon dismantling previously authorized vaccines at the FDA.

Høeg has repeatedly called for halting certain childhood vaccine recommendations in the US in order to be more like the Danish model, a society with comprehensive healthcare and a citizenry approximately the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Background

Høeg has no obvious background in medication creation, regulation or administrative roles, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a scientific study. She lacks experience in leading a large organization. She lacks background in pharmaceutical oversight.”

Former commissioners of CBER would “be deeply familiar with laws and regulations and the science of drug development”, commented Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who ran the center have had.”

The drug center has an enormous portfolio at the agency, Woodcock pointed out.

“The public just focuses on the novel medication approvals, but the generic drug division clears numerous off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and more, and each of these must be supervised,” Woodcock noted. “The area you overlook, that is precisely what that I always told people is going to cause problems.”

Additionally, a significant management component to the role, which manages more than 5,000 employees. “It is a huge administrative position, if you do it right,” Woodcock said.

Official Statement and Disputed Policies

In response to questions about Høeg’s fitness for the role and whether this selection signifies more teamwork among FDA leaders on immunizations, a representative stated that the “concerns are based on inaccurate presumptions”.

“Her resume is consistent with the duties of her position,” the official said, pointing to the period Høeg spent guiding the agency head on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s new fast-track approval initiative, a controversial expedited medication authorization process that apparently concerned her predecessors. “How are these medications being selected for this voucher program? Who takes the decisions?” Dr. Howard asked. “There is a lot of lack of transparency going on at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards more relaxed regulations of most medications, with the exception of shots.”

Documented Past Work on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if problematic, track record, some experts have noted. She published a research paper using non-validated crowd-sourced reports to estimate the incidence of myocarditis after Covid immunization. She counseled the Florida top health official Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Part of her “wish list” for the current federal leadership encompassed changing regulations for recently developed shots and discontinuing “unnecessary” vaccines, she remarked after the election on a online show. At the FDA, Høeg has allegedly suggested barring young men from getting Covid vaccines.

“She is an complete ideologue who starts off with her preconceived notions and works backwards to accommodate the evidence in a extremely misleading, fraudulent manner,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|